Monday, November 06, 2006 9:37:21 AM
Just because they already made one commitment doesn't forestall another. The milestones don't have anything to do with GRNVAC1. Merck is using the telomerase-as-target in two of their own platforms.
It would, however, be interesting to know what the "joint development committee" is working on.
The licensing news on the LAMP today is also interesting. So much for the theory that GRNVAC1 is on the way out. Looks like they're securing the tech for the eventual commercial rollout. Apparently the rumors of its death were greatly exaggerated. Along with the faulty notion that primates were needed in the hESC IND package, I hope nobody paid any money to our pseudo analyst for his views.
Recent GERN News
FEATURED North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • Jul 18, 2024 9:00 AM
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
